Literature DB >> 8985408

Fusion of bovine leukemia virus with target cells monitored by R18 fluorescence and PCR assays.

S Zarkik1, F Defrise-Quertain, D Portetelle, A Burny, J M Ruysschaert.   

Abstract

PCR and R18 fluorescence dequenching assays have been combined to monitor the kinetics of fusion of bovine leukemia virus with target cells (CC81, OVK, or Raji). Antibodies raised against gp51 allow us to demonstrate that not only the hydrophobic N-terminal domain of the transmembrane glycoprotein gp30 but also specific domains of gp51 (amino acids 39 to 103) are involved in bovine leukemia virus-cell fusion.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 8985408      PMCID： PMC191109     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  25 in total

1.  THE CYCLE OF MULTIPLICATION OF VACCINIA VIRUS IN EARLE'S STRAIN L CELLS. I. UPTAKE AND PENETRATION.

Authors:  S DALES; R KAJIOKA
Journal:  Virology       Date:  1964-11       Impact factor: 3.616

2.  Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41.

Authors:  E O Freed; D J Myers; R Risser
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

3.  Identification of functional sites on bovine leukemia virus envelope glycoproteins using structural and immunological data.

Authors:  I Callebaut; D Portetelle; A Burny; J P Mornon
Journal:  Eur J Biochem       Date:  1994-06-01

4.  Topographical analysis by monoclonal antibodies of BLV-gp51 epitopes involved in viral functions.

Authors:  C Bruck; D Portetelle; A Burny; J Zavada
Journal:  Virology       Date:  1982-10-30       Impact factor: 3.616

5.  A fluorescence enhancement assay of cell fusion.

Authors:  P M Keller; S Person; W Snipes
Journal:  J Cell Sci       Date:  1977-12       Impact factor: 5.285

6.  The requirements for viral entry differ from those for virally induced syncytium formation in NIH 3T3/DTras cells exposed to Moloney murine leukemia virus.

Authors:  C A Wilson; J W Marsh; M V Eiden
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

7.  Monoclonal antibodies define eight independent antigenic regions on the bovine leukemia virus (BLV) envelope glycoprotein gp51.

Authors:  C Bruck; S Mathot; D Portetelle; C Berte; J D Franssen; P Herion; A Burny
Journal:  Virology       Date:  1982-10-30       Impact factor: 3.616

8.  Inactivation of PR8 influenza virus through the octadecylrhodamine B chloride membrane marker.

Authors:  H Wunderli-Allenspach; M Günthert; S Ott
Journal:  Biochemistry       Date:  1993-01-26       Impact factor: 3.162

9.  Fusogenic segments of bovine leukemia virus and simian immunodeficiency virus are interchangeable and mediate fusion by means of oblique insertion in the lipid bilayer of their target cells.

Authors:  V Vonèche; D Portetelle; R Kettmann; L Willems; K Limbach; E Paoletti; J M Ruysschaert; A Burny; R Brasseur
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

10.  Differential effects of a hydrophobic tripeptide on human immunodeficiency virus type 1 (HIV-1)-induced syncytium formation and viral infectivity.

Authors:  K Konopka; E Pretzer; N Düzgünes
Journal:  Biochem Biophys Res Commun       Date:  1995-03-08       Impact factor: 3.575
View more
  3 in total

Review 1.  The many mechanisms of viral membrane fusion proteins.

Authors:  L J Earp; S E Delos; H E Park; J M White
Journal:  Curr Top Microbiol Immunol       Date:  2005       Impact factor: 4.291

2.  A point mutation in the binding subunit of a retroviral envelope protein arrests virus entry at hemifusion.

Authors:  Tatiana Zavorotinskaya; Zhaohui Qian; John Franks; Lorraine M Albritton
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

Review 3.  Determinants of the Bovine Leukemia Virus Envelope Glycoproteins Involved in Infectivity, Replication and Pathogenesis.

Authors:  Alix de Brogniez; Jan Mast; Luc Willems
Journal:  Viruses       Date:  2016-03-24       Impact factor: 5.048
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.